CYP19A1 and breast cancer: This issue may be elucidated with the ongoing OPTIMA study, where premenopausal women with breast cancer receive either chemotherapy followed by ET (tamoxifen or an aromatase inhibitor) or undergo BCMS testing, with those obtaining a low-risk score receiving only ET25,26.